Tokyo, Japan – March 13, 2020 – LPIXEL Inc., a leader in image analysis and processing in life science and medical research, announced today the launch of its newly revamped website for EIRL aneurysm and EIRL basic. Through the EIRL series, LPIXEL aims to deliver high quality and efficient medical care by harnessing its advanced technologies. The new and improved websites offer quick and easy access to essential information, and simplified navigation for healthcare providers to send in their product-related inquiries.
EIRL aneurysm is Japan’s first deep learning-powered software as a medical device (SaMD) for brain MRI to receive approval from the Ministry of Health Labour and Welfare (MHLW). EIRL is designed to support the image interpretation process by identifying suspected aneurysms in brain MRI. More information here.
EIRL is the brain measurement tool which provides automatic measurements for parameters that are otherwise measured manually, including the Evans index, Callosal angle, and white matter hyperintensities. More information here.
EIRL is the collective name given to LPIXEL’s AI medical image diagnostic support technology. LPIXEL aims to provide solutions that enable more efficient, accurate diagnosis by implementing its unique algorithms to analyze medical data, such as brain MRI, chest X-rays, and colonoscopy.
LPIXEL is a leader in advanced image analysis and processing technology encompassing the life science field. Founded in March 2014, LPIXEL is dedicated to offering research facilities top-tier image analysis solutions and medical diagnosis technologies, both of which adopt advanced AI technology. The company is currently working in collaboration with the University of Tokyo Hospital, the National Cancer Center Japan and other research institutions to further the development of its AI-based medical diagnosis technology. For more information, please visit https://lpixel.net/en/.